Figure 2.

Impact of PPARγ agonism in skeletal muscle during LPS-induced endotoxaemia. Treatment with PPARγ agonists during endotoxaemia suppresses production of pro-inflammatory cytokines (e.g., tumour necrosis factor α: TNF-α). This results in reduced suppression of muscle AKT, and reduced transcriptional activity of Forkhead Box O (FOXO) transcription factors. Reduced activity of FOXO leads to suppression of factors important in increased muscle atrophy (MAFbx and MuRF1) as well as PDK4, a key protein in PDC inhibition.